Carmustine is a potent alkylating agent widely recognized for its application in oncology, particularly in the treatment of brain tumors and multiple myeloma. As a member of the nitrosourea class, it functions by interfering with DNA replication, making it effective against rapidly dividing cancer cells. Its unique ability to cross the blood-brain barrier enhances its efficacy in treating central nervous system malignancies, providing a critical therapeutic option where other treatments may fall short.

In addition to its primary use in cancer therapy, Carmustine is also employed in research settings, particularly in studies focused on the mechanisms of cancer resistance and the development of novel chemotherapeutic agents. Its versatility and effectiveness make it a valuable compound for both clinical and laboratory applications, offering researchers and healthcare professionals a reliable tool in the fight against cancer. With its established track record, Carmustine continues to be a cornerstone in cancer treatment protocols, demonstrating significant potential for improving patient outcomes.